ISSN:
1432-0843
Keywords:
Key words Limited-sampling model
;
Pharmacodynamics
;
Pharmacokinetics
;
Phase II
;
Topotecan
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Topotecan is a novel semisynthetic derivative of the anticancer agent camptothecin and inhibits the intranuclear enzyme topoisomerase I. The lactone structure of topotecan, which is in equilibrium with the inactive ring-opened hydroxy acid, is essential for this activity. We performed a pharmacokinetics study as part of phase II clinical trials in patients with various types of solid tumors, giving topotecan at 1.5 mg/m2 per day by 30-min infusion for 5 consecutive days, with courses being repeated every 3 weeks. Previously validated limited-sampling models, using concentration measurements in samples obtained 2 h after infusion, were used to calculate the area under the plasma concentration-time curves (AUCs) for both chemical forms. Samples were obtained from a total of 36 patients over 136 treatment days. The mean AUC of the closed-ring form (AUCclosed) was 8.74 (range 2.3–16.3) μM min per day, and the mean AUC of the ring-opened form (AUCopen) was 11.5 (range 3.2–46.0) μM min per day (interpatient variability 34–61%). In each patient the AUC values achieved on the 1st day of administration were similar to and, thus, predictive for those achieved during the following days, with a day-to-day variation of 7.39% being recorded for the AUCclosed and that of 12.6%, for the AUCopen. There was no drug accumulation during the 5 consecutive treatment days of each cycle. However, despite the large interpatient pharmacokinetic variability, the importance of regular drug monitoring on this schedule can be questioned, as the pharmacodynamic variability was relatively small.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/s002800050479
Permalink
